Engineered immune cells take on tough leukemia
NCT ID NCT04016129
First seen Apr 25, 2026 · Last updated Jun 19, 2026 · Updated 9 times
Summary
This study tests a new type of CAR T-cell therapy for people with B-cell leukemia that does not have the CD19 protein, often because it stopped responding to earlier CAR T treatment. The modified immune cells target six different markers on leukemia cells. The trial aims to see if this approach is safe and can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongxi Children Hospital
RECRUITINGShijiazhuang, Hebei, 050006, China
Contact
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified immune cells (CAR T-cells) targeting CD22, CD123, CD38, CD10, CD20, and TSLPR
What this could lead to
If successful, this could provide a new treatment option for patients whose leukemia no longer responds to standard CAR T-cell therapy.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. There are also risks of serious side effects from the cell infusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.